CIK 0001477845 · Non-accelerated filer<br>Smaller reporting company
Annovis Bio, Inc.
Sign in to watch- Ticker
- ANVS
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 262540421
- Phone
- 484-875-3192
- Business address
- 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
- Former names
- QR Pharma, Inc.
- Open-market buys, last 90 days
- $5,000,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$5,000,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-07 | McCarthy Reid Director | Grant or award · Stock Option (right to buy) | +4,000 | 4,000 | ||
| 2021-07-07 | Maccecchini Maria-Luisa President and CEO | Grant or award · Stock Option (right to buy) | +41,700 | 41,700 | ||
| 2021-07-07 | Hoffman Michael B Director | Grant or award · Stock Option (right to buy) | +4,500 | 4,500 | ||
| 2021-07-07 | Bruck Claudine Director | Grant or award · Stock Option (right to buy) | +4,000 | 4,000 | ||
| 2020-07-01 | Bruck Claudine Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2020-07-01 | White Mark K. Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2020-07-01 | Whelan, Jr. Robert M. Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2020-07-01 | Hoffman Michael B Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2020-04-09 | McGroarty Jeffrey Brian Chief Financial Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2020-04-09 | Maccecchini Maria-Luisa President and CEO | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2020-02-03 | McGroarty Jeffrey Brian Chief Financial Officer | Purchase | +19,336 | $7.15 | $138K | 52,669 |
| 2020-02-03 | McGroarty Jeffrey Brian Chief Financial Officer | Purchase | +164 | $7.17 | $1K | 52,833 |
| 2020-01-31 | Hoffman Michael B Director | Purchase | +33,333 | $6.00 | $200K | 47,619 |
| 2020-01-31 | Hoffman Michael B Director | Conversion | +158,730 | 206,349 | ||
| 2020-01-31 | Hoffman Michael B Director | Conversion | +1,137,942 | 1,344,291 | ||
| 2020-01-31 | Hoffman Michael B Director | Conversion | +55,884 | $4.80 | $268K | 1,400,175 |
| 2020-01-31 | Hoffman Michael B Director | Conversion · Series A-1 Preferred Stock | −222,222 | 0 | ||
| 2020-01-31 | Hoffman Michael B Director | Conversion · Series A Preferred Stock | −1,593,118 | 0 | ||
| 2020-01-31 | Hoffman Michael B Director | Conversion · Convertible Note | −55,884 | $4.80 | $268K | 0 |
| 2020-01-31 | Whelan, Jr. Robert M. Director | Purchase | +25,000 | $6.00 | $150K | 25,000 |
Page 6 of 8 · 142 trades